TALS vs. IBRX, TWST, RXRX, VCEL, DNLI, TARS, BEAM, SCLX, KYMR, and BCRX
Should you be buying Talaris Therapeutics stock or one of its competitors? The main competitors of Talaris Therapeutics include ImmunityBio (IBRX), Twist Bioscience (TWST), Recursion Pharmaceuticals (RXRX), Vericel (VCEL), Denali Therapeutics (DNLI), Tarsus Pharmaceuticals (TARS), Beam Therapeutics (BEAM), Scilex (SCLX), Kymera Therapeutics (KYMR), and BioCryst Pharmaceuticals (BCRX). These companies are all part of the "biological products, except diagnostic" industry.
Talaris Therapeutics vs.
Talaris Therapeutics (NASDAQ:TALS) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, community ranking, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.
ImmunityBio received 7 more outperform votes than Talaris Therapeutics when rated by MarketBeat users. Likewise, 48.78% of users gave ImmunityBio an outperform vote while only 48.15% of users gave Talaris Therapeutics an outperform vote.
Talaris Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -8,016.83%. ImmunityBio's return on equity of 0.00% beat Talaris Therapeutics' return on equity.
ImmunityBio has a consensus target price of $12.19, indicating a potential upside of 353.07%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than Talaris Therapeutics.
In the previous week, ImmunityBio had 14 more articles in the media than Talaris Therapeutics. MarketBeat recorded 14 mentions for ImmunityBio and 0 mentions for Talaris Therapeutics. ImmunityBio's average media sentiment score of 0.35 beat Talaris Therapeutics' score of 0.00 indicating that ImmunityBio is being referred to more favorably in the news media.
67.6% of Talaris Therapeutics shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 16.5% of Talaris Therapeutics shares are held by insiders. Comparatively, 83.4% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Talaris Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.
Talaris Therapeutics has higher earnings, but lower revenue than ImmunityBio. Talaris Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.
Summary
ImmunityBio beats Talaris Therapeutics on 13 of the 18 factors compared between the two stocks.
Get Talaris Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for TALS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Talaris Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:TALS) was last updated on 4/24/2025 by MarketBeat.com Staff
